Prometrium Pharmacokinetics (ADME): How Micronized Progesterone Is Absorbed, Distributed, Metabolized, and Excreted

Why Micronization Matters for Oral Progesterone Absorption

Native crystalline progesterone is practically insoluble in water and has negligible oral bioavailability. Micronization reduces particle diameter to roughly 10 micrometers, dramatically increasing surface area and dissolution rate in the gastrointestinal tract [1]. This process, combined with suspension in peanut oil within the Prometrium capsule, allows enough drug to reach systemic circulation to produce clinically meaningful serum concentrations.

Even with micronization, oral bioavailability remains approximately 10% [2]. The low figure reflects two barriers: incomplete absorption across the intestinal epithelium and aggressive first-pass hepatic extraction. Despite this, the 200 mg and 300 mg oral doses produce serum progesterone concentrations sufficient for endometrial protection in postmenopausal hormone therapy. The PEPI trial (N=875) confirmed that 200 mg of micronized progesterone taken cyclically for 12 days per month prevented endometrial hyperplasia while preserving the favorable HDL cholesterol effects of conjugated equine estrogens [3].

The 2022 Endocrine Society clinical practice guideline on menopausal hormone therapy states: "Micronized progesterone is the preferred progestogen for endometrial protection because of its more favorable cardiovascular and metabolic profile compared with synthetic progestins" [4]. That preference traces back directly to the pharmacokinetic advantages of the micronized formulation.

Absorption: Peak Levels, Food Effects, and Dose Proportionality

After a single 200 mg oral dose taken with food, Prometrium reaches a mean Cmax of approximately 17 to 38 ng/mL within 2 to 4 hours [2]. There is wide interpatient variability, with some subjects reaching peak levels as early as 1 hour and others not until 6 to 8 hours post-dose. This variability stems from differences in gastric emptying, intestinal transit time, and hepatic enzyme activity.

Food has a pronounced effect on absorption. A high-fat meal increases Cmax by 50 to 60% and AUC by a similar magnitude relative to fasting conditions [2]. The FDA-approved labeling instructs patients to take Prometrium at bedtime, which serves two purposes: it aligns dosing with a post-dinner fed state, and it shifts the sedative peak of the allopregnanolone metabolite into the sleep period.

Dose proportionality is roughly linear between 100 mg and 300 mg, though the relationship is not perfectly proportional at higher doses [5]. At 100 mg, mean Cmax values are approximately 8 to 15 ng/mL. At 300 mg, peak concentrations range from 25 to 50 ng/mL. These ranges overlap substantially between doses because of the high coefficient of variation (40 to 70%) seen in pharmacokinetic studies of oral progesterone [2].

Compared with intramuscular or vaginal progesterone, oral micronized progesterone produces lower and more variable serum concentrations but generates significantly higher levels of the 5α-reduced metabolites, including allopregnanolone [6]. This metabolite profile is a direct consequence of the oral route and its obligatory passage through the liver.

Distribution: Protein Binding and Tissue Penetration

Progesterone is highly lipophilic with a large apparent volume of distribution. Protein binding exceeds 96%, with albumin carrying the bulk of circulating drug and corticosteroid-binding globulin (CBG) contributing a smaller fraction [2]. Sex hormone-binding globulin (SHBG) does not meaningfully bind progesterone, which distinguishes it from estradiol and testosterone in terms of transport dynamics.

The high lipophilicity allows progesterone to cross the blood-brain barrier readily. This property explains why oral progesterone produces central nervous system effects (sedation, anxiolysis) that are not observed with vaginal or transdermal delivery at equivalent serum progesterone levels [7]. The CNS effects are mediated not by progesterone itself but by allopregnanolone generated during first-pass metabolism, which then distributes into brain tissue.

Progesterone also accumulates in adipose tissue, creating a depot effect. In obese patients, the larger volume of distribution may lower peak serum concentrations and extend the apparent half-life [8]. Clinicians should be aware that standard dosing may produce different pharmacokinetic profiles in patients with BMI <25 versus BMI >35, though the FDA labeling does not include specific dose adjustments for body weight.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, has noted: "The pharmacokinetic profile of oral micronized progesterone, including its conversion to neuroactive metabolites, gives it properties that are distinct from synthetic progestins and should inform clinical decision-making about route of administration" [9].

Metabolism: First-Pass Hepatic Biotransformation and the Allopregnanolone Pathway

The liver extracts the majority of absorbed progesterone during its first pass through the portal circulation. Two cytochrome P450 enzymes dominate this process: CYP2C19 performs the initial oxidative steps, while CYP3A4 contributes to secondary metabolic pathways [10]. Genetic polymorphisms in CYP2C19 are clinically relevant. Poor metabolizers (approximately 2 to 5% of Caucasians and 15 to 20% of East Asian populations) may experience higher progesterone levels and lower allopregnanolone production, potentially altering both the endometrial and sedative effects of the drug [10].

The metabolic cascade follows a defined sequence. Progesterone is first reduced by 5α-reductase to 5α-dihydroprogesterone, which is then converted by 3α-hydroxysteroid dehydrogenase to allopregnanolone (5α-pregnan-3α-ol-20-one). Allopregnanolone is a potent positive allosteric modulator of the GABA-A receptor, producing anxiolytic, sedative, and anticonvulsant effects at nanomolar concentrations [7]. After a 200 mg oral dose, allopregnanolone levels reach 2 to 5 ng/mL, concentrations that are pharmacologically active at the GABA-A receptor [6].

A parallel pathway converts progesterone to 20α-dihydroprogesterone, an essentially inactive metabolite. Both allopregnanolone and 20α-dihydroprogesterone undergo phase II conjugation (glucuronidation and sulfation) in the liver before renal excretion [2].

The hepatic metabolism has practical drug interaction implications. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) can increase progesterone AUC by 30 to 50% [11]. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) can reduce progesterone exposure by a similar magnitude, potentially compromising endometrial protection. The FDA label warns against concomitant use with strong CYP3A4 inducers [2].

One underappreciated interaction involves grapefruit juice, which inhibits intestinal CYP3A4 and can increase oral progesterone bioavailability by approximately 20 to 30% [12]. While this is a modest effect compared with ketoconazole, patients consuming large quantities of grapefruit products daily may notice increased sedation.

Excretion: Renal Elimination and Terminal Half-Life

The kidneys handle 50 to 60% of progesterone dose elimination as glucuronide and sulfate conjugates of progesterone metabolites [2]. Biliary excretion accounts for an additional 10 to 20%, with the remainder eliminated through fecal routes. Unchanged progesterone in urine is negligible, consistent with the near-complete hepatic extraction.

The apparent terminal elimination half-life after a single oral dose is approximately 16 to 18 hours, though some pharmacokinetic analyses report values ranging from 12 to 25 hours depending on the assay method and sampling duration [5]. The wide range reflects the complexity of progesterone's metabolic disposition: multiple sequential metabolic steps, redistribution from adipose tissue, and enterohepatic recirculation of conjugated metabolites all contribute to a multicompartment elimination profile.

At steady state with daily bedtime dosing of 200 mg, trough progesterone concentrations (measured approximately 20 to 24 hours post-dose) range from 1 to 5 ng/mL [2]. These trough levels are sufficient to maintain progesterone receptor activation in the endometrium but may not fully suppress estrogen-driven proliferative signaling in all patients, which is why the PEPI trial used a 12-day-per-cycle regimen rather than continuous daily dosing for the cyclic arm [3].

Renal impairment has not been formally studied in dedicated pharmacokinetic trials for Prometrium. Because the parent drug is eliminated almost entirely through hepatic metabolism, mild to moderate renal impairment is unlikely to alter progesterone exposure meaningfully. Conjugated metabolites may accumulate in severe renal impairment (eGFR <30 mL/min), but the clinical significance of this accumulation is unknown [2].

Hepatic impairment is a greater concern. In patients with moderate hepatic dysfunction (Child-Pugh B), progesterone clearance is reduced and metabolite ratios shift, with relatively less allopregnanolone production and more accumulation of the parent compound [13]. The FDA label does not provide specific dose adjustments for hepatic impairment but notes that patients with liver disease may have increased sedation and should be monitored closely.

Clinical Implications: How ADME Shapes Dosing Decisions

The pharmacokinetic profile of oral micronized progesterone directly informs three areas of clinical practice: timing of administration, route selection, and dose individualization.

Bedtime dosing is not optional. The 2 to 4 hour Tmax means that peak allopregnanolone levels coincide with 2 to 4 hours post-dose, producing maximal sedation during that window. Patients who take Prometrium in the morning report dizziness, drowsiness, and impaired concentration at rates significantly higher than those dosing at bedtime [2]. The sedation is a pharmacokinetic consequence, not an idiosyncratic reaction.

Route selection matters when metabolite profile is important. Vaginal micronized progesterone (Endometrin, Crinone) bypasses first-pass metabolism, producing lower allopregnanolone levels but higher local endometrial progesterone concentrations through a "uterine first-pass effect" [14]. For patients who cannot tolerate oral progesterone sedation or who have hepatic impairment, vaginal administration achieves endometrial protection without the neuroactive metabolite burden.

The Endocrine Society's 2015 guideline on the management of menopause-associated vasomotor symptoms acknowledges that "micronized progesterone may have advantages over medroxyprogesterone acetate for breast safety, based on observational data from the E3N cohort, where oral micronized progesterone was not associated with increased breast cancer risk over a mean 8.1 years of follow-up" [15]. This observation may relate partly to the drug's pharmacokinetics: the short effective half-life and pulsatile exposure pattern of bedtime-only oral progesterone may produce less sustained progesterone receptor activation in breast tissue than the continuous receptor occupancy produced by synthetic progestins with 24-hour-plus half-lives.

Prometrium Versus Synthetic Progestins: A Pharmacokinetic Comparison

The ADME differences between micronized progesterone and synthetic progestins like medroxyprogesterone acetate (MPA) are not trivial. They produce meaningfully different clinical profiles.

MPA has an oral bioavailability of approximately 0.6 to 10% (depending on the formulation) and a terminal half-life of 30 to 60 hours [16]. This long half-life produces sustained, near-continuous progesterone receptor activation. MPA does not produce allopregnanolone, so it lacks the sedative effect of oral micronized progesterone. It does, however, bind to the androgen and glucocorticoid receptors, contributing to androgenic and anti-mineralocorticoid side effects that progesterone largely avoids.

In the PEPI trial, micronized progesterone 200 mg for 12 days per cycle produced equivalent endometrial protection to MPA 10 mg for 12 days per cycle, with mean endometrial hyperplasia rates of 1% in both groups at 36 months versus 34% in the unopposed estrogen arm [3]. The equivalent efficacy despite micronized progesterone's lower bioavailability and shorter half-life reflects the importance of local endometrial drug exposure and the sufficiency of pulsatile progesterone receptor activation for anti-proliferative effects.

Norethindrone acetate, another common synthetic progestin, has a bioavailability of approximately 64% and a half-life of 8 to 11 hours [16]. Its metabolic pathway does not generate neuroactive steroids, but it does produce ethinyl estradiol as a minor metabolite, which has implications for patients with estrogen-sensitive conditions.

These pharmacokinetic distinctions between progesterone and synthetic progestins are the biological basis for the clinical observation that micronized progesterone is generally better tolerated, with fewer androgenic side effects, less adverse impact on lipids, and potentially lower breast cancer risk in long-term observational studies [15].

Special Populations: Obesity, Aging, and Hepatic Impairment

Three patient populations warrant specific pharmacokinetic consideration.

In obese patients (BMI >35), the expanded adipose tissue compartment increases the volume of distribution and may reduce Cmax while prolonging the apparent half-life [8]. No formal dose-adjustment studies exist, but clinicians should be aware that standard 200 mg dosing may produce lower peak levels. Monitoring with serum progesterone levels drawn 4 to 6 hours post-dose can confirm adequate absorption when clinical response is uncertain.

In women over age 65, hepatic blood flow and CYP enzyme activity decline, potentially reducing first-pass extraction and increasing oral bioavailability by 20 to 30% [13]. This population may experience more pronounced sedation at standard doses. Starting at 100 mg and titrating based on tolerability is a reasonable approach, though no guideline mandates this adjustment.

Hepatic impairment reduces both the rate and extent of progesterone metabolism. Patients with cirrhosis (Child-Pugh B or C) may have two- to threefold increases in progesterone AUC [13]. The FDA label states that Prometrium should be used with caution in patients with hepatic dysfunction and that these patients should be monitored for excessive sedation and other progesterone-related side effects [2]. For patients with significant hepatic impairment who require progestogen therapy, vaginal micronized progesterone is the preferred route because it avoids the hepatic first-pass effect entirely.